<DOC>
	<DOCNO>NCT00002313</DOCNO>
	<brief_summary>To evaluate clinical toxicity , safety , potential anti-HIV activity intravenous nystatin patient HIV infection complete protocol FDA 103C . To evaluate safety potential antiviral activity intravenous nystatin oral didanosine ( ddI ) administer alternate regimen patient population .</brief_summary>
	<brief_title>A Study Nystatin HIV-Infected Patients</brief_title>
	<detailed_description>Patients complete protocol FDA 103B offer option receive extended maintenance . Patients receive prior ddI treat either intravenous nystatin alone ( dose level administer FDA 103B ) regimen intravenous nystatin ddI alternate 3-week cycle . Treatment continue 12 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Completed 12 week therapy intravenous nystatin protocol FDA 103B . No evidence toxicity progression disease protocol FDA 103B . ( See protocol FDA 103B initial entry requirement . ) Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Nystatin</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>